Use of C5a receptor antagonist in the treatment of fibrosis

Details Use of C5a receptor antagonist in the treatment of fibrosis Use of C5a receptor antagonist in the treatment of fibrosis

2011-04-05

2011-04-05

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S009100

Reexamination Certificate

active

07919459

ABSTRACT:
This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred embodiment, the antagonist is a C5a receptor antagonist, more preferably a cyclic peptide antagonist of the C5a receptor. In particular, the invention provides a method of prevention, treatment or alleviation of a fibrotic condition, comprising the step of administering an effective amount of an antagonist of a G protein-coupled receptor to a subject in need of such treatment.

REFERENCES:
patent: 4692511 (1987-09-01), Hahn
patent: 5643872 (1997-07-01), Ali et al.
patent: 5677426 (1997-10-01), Fong et al.
patent: 5767079 (1998-06-01), Glaser et al.
patent: 5789542 (1998-08-01), McLaughlin et al.
patent: 5807824 (1998-09-01), van Oostrum et al.
patent: 5916898 (1999-06-01), Edwards et al.
patent: 5935796 (1999-08-01), Fosang et al.
patent: 6821950 (2004-11-01), Fairlie et al.
patent: 7410945 (2008-08-01), Woodruff et al.
patent: 7579432 (2009-08-01), Taylor et al.
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2002/0106732 (2002-08-01), Miyazono et al.
patent: 2002/0147302 (2002-10-01), Abdel-Magid et al.
patent: 2005/0119167 (2005-06-01), Abbenante et al.
patent: 2006/0135411 (2006-06-01), Woodruff et al.
patent: 2006/0217530 (2006-09-01), Maxwell et al.
patent: 2006/0234921 (2006-10-01), Shiels
patent: 2007/0021329 (2007-01-01), Shiels et al.
patent: 2007/0054841 (2007-03-01), Shiels et al.
patent: 2007/0249526 (2007-10-01), Abbenante et al.
patent: 2008/0058252 (2008-03-01), Taylor et al.
patent: 2009/0004264 (2009-01-01), Woodruff et al.
patent: 199880926 (1997-06-01), None
patent: 1 308 438 (2003-05-01), None
patent: 98/45309 (1998-10-01), None
patent: 98/54180 (1998-12-01), None
patent: 99/00406 (1999-01-01), None
patent: 99/02501 (1999-01-01), None
patent: WO 99/00406 (1999-01-01), None
patent: 02/14265 (2002-02-01), None
patent: 02/24222 (2002-03-01), None
patent: 03/033528 (2003-04-01), None
patent: 03/086448 (2003-10-01), None
patent: 2004/035080 (2004-04-01), None
Anaya et al., “Pulmonary Involvement in Rheumatoid Arthritis,” Semin. Arthritis Rheum., 24(4): 242-254, Feb. 1995.
Arumugam et al.,“A Small Molecule C5a Receptor Antagonist Protects Kidneys from Ischemia/Reperfusion Injury in Rats,” Kidney International, 63:134-42, Jan. 2003.
Arumugam et al.,“Protective Effect of a New C5a Receptor Antagonist against Ischemia-Reperfusion Injury in the Rat Small Intestine,” J. Surg. Res.,103:260-7, Apr. 2002.
Baskaran et al., “Dynamics of Tissue Neutrophil Sequestration After Cutaneous Burns in Rats,” J. Surg. Res., 93 (1):88-96, Sep. 2000.
Beames et al., “Studies on Intramolecular Alkylation. IV* The Preparation of Spirodienones from Phenolic Diazoketones” Aus. J. Chem., 27(6):1257-68, Jun. 1974.
Benoition et al., “Studies on Sensitivity to Racemization of Activated Residues in Couplings of N-benzyloxycarbonyldipeptides,” Int. J. Pep. Prot. Res., 40(6):559-66, Dec. 1992.
Bernadelli et al., “Section VII. Trends and Perspectives,” Ann. Rep. Med. Chem., 37:257-277, Oct. 2002.
Bertrand et al.,“CCR3 Blockade as a New Therapy for Asthma,” Exp. Opin. Invents. Drugs 9(1):43-52, Jan. 2000.
Bodansky et al., “Introductions of Amine Protecting Groups,” The Practice of Peptide Synthesis; 2nd, rev. ed., Springer-Verlag: Berlin, New York, Jun. 1994.
Brady et al., “Large-Scale Synthesis of a Cyclic Hexapeptide Analogue of Somatostatin,” J. Org. Chem., 52(5):764-769, Mar. 1987.
Cain et al., “Modulation of Ligand Selectivity by Mutation of the First Extracellular Loop of the Human C5a Receptor,” Biochem. Pharmacol., 61(12):1571-9, Jun. 15, 2001.
Chan et al., “Basic Procedures” in Fmoc Solid Phase Peptide Synthesis: A Practical Approach; Oxford University Press, 2000.
Cheng, “Section VII. Trends and Perspectives,” Annual Reports in Medicinal Chemistry, 31:337-355, Feb. 1995.
Dinarello, “Dissociation of Transcription from Translation of Human IL-1B: Induction of Steady State mRNA by Adherence or Recombinant C5a in the Absence of Translation,” Soc. Exp. Biol. Med., 200:228-232, Jun. 1992.
Diop et al. “Pregabalin (CI-1008) Inhibits the Trinitrobenzene Sulfonic Acid-Induced Chronic Colonic Allodynia in the Rat,” J. Pharmacol. Exp. Ther., http://jpet.aspetjournals.org, 302(3):1013-1022, Sep. 2002.
Fields et al, “Solid Phase Peptide Synthesis Utilizing 9-fluorenylmethoxycarbonyl Amino Acids,” Int. J. Pept. Prot. Res., 35(3):161-214, Mar. 1990.
Fukunaga et al., “A Novel Diamino-Pyridine Derivative (IS-741) Attenuates Rat lieitis Induced by Trinitrobenzene Sulfonic Acid,” J. Gastroenterology, Springer-Verlag; 38(5):451-9, May 2003.
Galatis, P., “Section VII. Trends and Perspectives,” Annu. Rep. Med. Chem., 32:305-326, 1997.
Gao et al., “Recent Advances in Neurokinin Receptor Antagonists,” Curr. Med. Chem., 6(5):375-388, May 1999.
Gaudilliere et al. “Section VII. Trends and Perspectives,” Annu. Rep. Med. Chem., 36:293-318, 2001.
Gaudilliere et al., “Section VII. Trends and Perspectives,” Annu. Rep. Med. Chem., 35:331-356, 2000.
Harkin et al., “Complement C5a Receptor Antagonist Attenuates Multiple Organ Injury in a Model of Ruptured Abdominal Aortic Aneurysm,” J. Vasc. Surg., 39(1):196-206, Jan. 2004.
Haynes et al., “Inhibition of C5a-Induced Neutrophil Chemotaxis and Macrophage Cytokine Production in Vitro by a New C5a Receptor Antagonist,” Biochem. Pharmacol., Australia, 60(5):729-33, Sep. 1, 2000.
Heller et al., “Selection of a C5a Receptor Antagonist from Phage Libraries Attenuating the Inflammatory Response in Immune Complex Disease and Ischemia-Reperfusion Injury,” J. Immunol. 163(2):985-94, Jul. 15, 1999.
Ikeda et al., Simvastatin Attenuates Trinitrobenzene Sulfonic Acid-Induced Colitis, But Not Oxazalone-Induced Colitis, Dig. Dis. Sci., 53(7):1869-75, Jan. 2008.
Johnson et al.,“Heterotrimeric G Protein Signalling: Role in Asthma and Allergic Inflammation” J. Allergy Clin. Immunol., 109(4):592-602, Apr. 2002.
Makrides, “Therapeutic Inhibition of the Complement System,” Pharmacol. Rev., 50(1):59-87, Mar. 1998.
Morikis et al., “Structural Aspects and Design of Low-Molecular-Mass Complement Inhibitors,” Biochem. Soc. Trans., 30(Pt. 6):1026-36, Nov. 2002.
Morris et al.,“Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon,” Gastroenterology, 96(3):795-803, Mar. 1989.
Owen et al., “Chemokine Receptors in Airway Disease: Which Receptor to Target?,” Pulmonary Pharmacology and Therapeutics, 14(3):193-202, Jun. 2001.
Packowski et al., “Pharmacological Characterization of Antagonists of the C5a Receptor,” Brit. J. Pharmacol., 128(7):1461-66, Dec. 1999.
Piccolo et al., “Chemoctactic Mediator Requirements in Lung Injury Following Skin Burns in Rats,” Exp. Molec. Pathol., 66(3):220-226, Aug. 1999.
Reid et al., “A Convergent Solution-Phase Syntheis of the Macrocycle Ac-Phe-[Orn-Pro-D-Cha—Trp-Arg], A Potent New Antiinflammatory Drug,” J. Org Chem., 68(11):4464-4471, May 30, 2003.
Roschmann et al., “Pulmonary Fibrosis in Rheumatoid Arthritis: A Review of Clinical Features and Therapy,” Semin. Arthritis Rheum., 16(3):174-185, Feb. 1987.
Schmid et al., “Requirement for C5a In Lung Vascular Injury Following Thermal Trauma to Rat Skin,” Shock, 8(2):119-124, Mar. 31, 1997.
Schuda et al., “A Short and Efficient Synthesis of (3S, 4S)-4-[(tert-Butyloxcarbonyl)amino]-5-cyclohexyl-3-hydroxypentanoic Acid Ethyl Ester,” J. Org. Chem., 53:873-875, Feb. 15, 1988.
Short et al., “Effects of New C5a Receptor Antagonist on C5a- and Endotoxin

Affiliated with

Also associated with

Rating

Use of C5a receptor antagonist in the treatment of fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of C5a receptor antagonist in the treatment of fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of C5a receptor antagonist in the treatment of fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2681059